HC Wainwright & Co. Maintains Buy on Atara Biotherapeutics, Raises Price Target to $28
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on Atara Biotherapeutics (NASDAQ:ATRA) and raises the price target from $27 to $28.
June 14, 2023 | 10:21 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Atara Biotherapeutics and raises the price target from $27 to $28.
The news of HC Wainwright & Co. maintaining a Buy rating on Atara Biotherapeutics and raising the price target from $27 to $28 is positive for the stock. This indicates that the analyst has confidence in the company's performance and potential growth, which could lead to an increase in demand for the stock and a short-term positive impact on its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100